Therapeutic advances in hormone-dependent cancers: Focus on prostate, breast and ovarian cancers

Michael Ulm, Arvind V. Ramesh, Keely M. McNamara, Suriyan Ponnusamy, Hironobu Sasano, Ramesh Narayanan

Research output: Contribution to journalReview article

Abstract

Hormonal cancers affect over 400,000 men and women and contribute collectively to over 100,000 deaths in the United States alone. Thanks to advances in the understanding of these cancers at the molecular level and to the discovery of several disease-modifying therapeutics, the last decade has seen a plateauing or even a decreasing trend in the number of deaths from these cancers. These advanced therapeutics not only effectively slow the growth of hormonal cancers, but also provide an insight on how these cancers become refractory and evolve as an altogether distinct subset. This review summarizes the current therapeutic trends in hormonal cancers, with focus on prostate, breast and ovarian cancers. The review discusses the clinical drugs being used now, promising molecules that are going through various stages of development and makes some predictions on how the therapeutic landscape will shift in the next decade.

Original languageEnglish (US)
Pages (from-to)R10-R26
JournalEndocrine Connections
Volume8
Issue number2
DOIs
StatePublished - Jan 1 2019

Fingerprint

Ovarian Neoplasms
Prostatic Neoplasms
Hormones
Breast Neoplasms
Neoplasms
Therapeutics
Growth
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Therapeutic advances in hormone-dependent cancers : Focus on prostate, breast and ovarian cancers. / Ulm, Michael; Ramesh, Arvind V.; McNamara, Keely M.; Ponnusamy, Suriyan; Sasano, Hironobu; Narayanan, Ramesh.

In: Endocrine Connections, Vol. 8, No. 2, 01.01.2019, p. R10-R26.

Research output: Contribution to journalReview article

Ulm, Michael ; Ramesh, Arvind V. ; McNamara, Keely M. ; Ponnusamy, Suriyan ; Sasano, Hironobu ; Narayanan, Ramesh. / Therapeutic advances in hormone-dependent cancers : Focus on prostate, breast and ovarian cancers. In: Endocrine Connections. 2019 ; Vol. 8, No. 2. pp. R10-R26.
@article{63872a10634140a2ad223a7fa80837e8,
title = "Therapeutic advances in hormone-dependent cancers: Focus on prostate, breast and ovarian cancers",
abstract = "Hormonal cancers affect over 400,000 men and women and contribute collectively to over 100,000 deaths in the United States alone. Thanks to advances in the understanding of these cancers at the molecular level and to the discovery of several disease-modifying therapeutics, the last decade has seen a plateauing or even a decreasing trend in the number of deaths from these cancers. These advanced therapeutics not only effectively slow the growth of hormonal cancers, but also provide an insight on how these cancers become refractory and evolve as an altogether distinct subset. This review summarizes the current therapeutic trends in hormonal cancers, with focus on prostate, breast and ovarian cancers. The review discusses the clinical drugs being used now, promising molecules that are going through various stages of development and makes some predictions on how the therapeutic landscape will shift in the next decade.",
author = "Michael Ulm and Ramesh, {Arvind V.} and McNamara, {Keely M.} and Suriyan Ponnusamy and Hironobu Sasano and Ramesh Narayanan",
year = "2019",
month = "1",
day = "1",
doi = "10.1530/EC-18-0425",
language = "English (US)",
volume = "8",
pages = "R10--R26",
journal = "Endocrine Connections",
issn = "2049-3614",
publisher = "BioScientifica Ltd.",
number = "2",

}

TY - JOUR

T1 - Therapeutic advances in hormone-dependent cancers

T2 - Focus on prostate, breast and ovarian cancers

AU - Ulm, Michael

AU - Ramesh, Arvind V.

AU - McNamara, Keely M.

AU - Ponnusamy, Suriyan

AU - Sasano, Hironobu

AU - Narayanan, Ramesh

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Hormonal cancers affect over 400,000 men and women and contribute collectively to over 100,000 deaths in the United States alone. Thanks to advances in the understanding of these cancers at the molecular level and to the discovery of several disease-modifying therapeutics, the last decade has seen a plateauing or even a decreasing trend in the number of deaths from these cancers. These advanced therapeutics not only effectively slow the growth of hormonal cancers, but also provide an insight on how these cancers become refractory and evolve as an altogether distinct subset. This review summarizes the current therapeutic trends in hormonal cancers, with focus on prostate, breast and ovarian cancers. The review discusses the clinical drugs being used now, promising molecules that are going through various stages of development and makes some predictions on how the therapeutic landscape will shift in the next decade.

AB - Hormonal cancers affect over 400,000 men and women and contribute collectively to over 100,000 deaths in the United States alone. Thanks to advances in the understanding of these cancers at the molecular level and to the discovery of several disease-modifying therapeutics, the last decade has seen a plateauing or even a decreasing trend in the number of deaths from these cancers. These advanced therapeutics not only effectively slow the growth of hormonal cancers, but also provide an insight on how these cancers become refractory and evolve as an altogether distinct subset. This review summarizes the current therapeutic trends in hormonal cancers, with focus on prostate, breast and ovarian cancers. The review discusses the clinical drugs being used now, promising molecules that are going through various stages of development and makes some predictions on how the therapeutic landscape will shift in the next decade.

UR - http://www.scopus.com/inward/record.url?scp=85064726172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064726172&partnerID=8YFLogxK

U2 - 10.1530/EC-18-0425

DO - 10.1530/EC-18-0425

M3 - Review article

AN - SCOPUS:85064726172

VL - 8

SP - R10-R26

JO - Endocrine Connections

JF - Endocrine Connections

SN - 2049-3614

IS - 2

ER -